The organ distribution of the tumor-associated carcinoembryonic antigen (CEA), and that of the normal tissue component NCA (non-specific cross-reacting antigen) have been investigated in the fetus. Organ extracts from five fetuses between 14 and 21 weeks of age were analysed by radioimmunoassay using specific antisera. CEA was detected in large amounts (800--1,650 ng/g) in fetal colon and in barely detectable amounts in lung and placental tissue. This differed from NCA, which could be detected in almost all organ extracts analysed. The highest concentration of NCA was measured in fetal colon and the content increased with the gestational age of the fetus. High amounts of NCA were also found in the liver, spleen and placental tissue. The gel elution profiles of CEA and NCA from an amniotic fluid pool and a pool of colonic extracts were also determined. CEA eluted similarly to the marker 125I--CEA purified from liver metastasis of colonic carcinoma. The NCA-reactive material was found in three distinct peaks.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ijc.2910250112 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic relevance of CD163 immune cells in patients with metastatic breast cancer.
Cancer Immunol Immunother
January 2025
Department of Clinical Sciences Lund, Division of Oncology, Lund University, 221 84, Lund, Sweden.
Metastatic breast cancer (MBC) is generally considered an incurable disease and even though new treatments are available, the median survival is approximately three years. The introduction of immune therapies for MBC highlights the importance of the immune system in cancer progression and treatment. CD163 anti-inflammatory myeloid cells, including tumor associated macrophages (TAMs), are known to be of relevance in early breast cancer but their role in MBC is not yet established.
View Article and Find Full Text PDFMicrobiome in urologic neoplasms: focusing on tumor immunity.
Front Immunol
December 2024
Department of Urology, The First People's Hospital of Xiushui, Jiujiang, Jiangxi, China.
Urological tumors are an important disease affecting global human health, and their pathogenesis and treatment have been the focus of medical research. With the in - depth study of microbiomics, the role of the microbiome in urological tumors has gradually attracted attention. However, the current research on tumor - associated microorganisms mostly focuses on one type or one site, and currently, there is a lack of attention to the microbiome in the immunity and immunotherapy of urological tumors.
View Article and Find Full Text PDFImaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer.
Proc Natl Acad Sci U S A
December 2024
Laboratory of Myeloid Cell Immunology, Vlaams Instituut voor Biotechnologie Center for Inflammation Research, Brussels 1050, Belgium.
Article Synopsis
- Immunotherapies are effective for immune-related diseases like cancer, but patient responses vary, making personalization of treatments essential.
- A novel nanobody-based immunotracer targeting CD163 was developed, which specifically binds to CD163 on macrophages without activating unwanted immune responses.
- This tracer enables noninvasive imaging that distinguishes immunotherapy responders from nonresponders by visualizing differences in CD163 macrophage distribution in tumors, aiding in predicting and monitoring treatment success.
Correlation of histological immunophenotype in papillary renal cell carcinoma with gene signatures related to the therapeutic effect of systemic therapy.
Pathol Res Pract
December 2024
Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
To predict the therapeutic response of systemic therapy, comprehensive analyses of the tumor microenvironment in papillary renal cell carcinoma (pRCC) have been conducted previously using immunohistochemistry and RNA sequencing. This study aimed to evaluate the correlation between hematoxylin and eosin-based histological immunophenotypes and gene signatures employed in several clinical trials predicting responsiveness to immune checkpoint inhibitors and tyrosine kinase inhibitors, using data from the Cancer Genome Atlas (TCGA)-KIRP cohort (n = 254). Herein, we evaluated tumor-associated immune cells (TAICs) using three methodologies previously reported in clear cell RCC: a 3-tier immunophenotype (desert, excluded, and inflamed) based on the spatial distribution of TAICs; a 4-tier immunophenotype (cold, immune-low, excluded, and hot) considering both the location and degree of TAICs; and an inflammation score (score 0, 1, and 2) focusing only on the degree of TAICs.
View Article and Find Full Text PDFTumor-associated macrophages contribute to cholangiocarcinoma progression and chemoresistance through activation of ID1.
Ann Hepatol
December 2024
Department of Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, China. Electronic address:
Introduction And Objectives: Tumor-associated macrophages (TAM) can influence both cancer growth and chemoresistance, but the specific mechanisms involved in these processes in cholangiocarcinoma (CCA) are unclear.
Materials And Methods: We explored the distribution of TAM in CCA samples by multiplex immunofluorescence staining and tested the effects of TAM on CCA in vitro and in vivo. We then investigated the mechanisms underlying these effects using the Luminex assay, RNA sequencing, western blotting, flow cytometry, and co-immunoprecipitation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!